Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib.

Cole AL, Wood WA Jr, Muluneh B, Lund JL, Elston Lafata J, Dusetzina SB.

JCO Oncol Pract. 2020 Mar 20:JOP1900301. doi: 10.1200/JOP.19.00301. [Epub ahead of print]

PMID:
32196424
2.

Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer.

Corty RW, Langworthy BW, Fine JP, Buse JB, Sanoff HK, Lund JL.

Oncologist. 2020 Mar 17. doi: 10.1634/theoncologist.2019-0570. [Epub ahead of print]

3.

Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility.

Rivera DR, Gokhale MN, Reynolds MW, Andrews EB, Chun D, Haynes K, Jonsson-Funk ML, Lynch KE, Lund JL, Strongman H, Bhullar H, Raman SR.

Pharmacoepidemiol Drug Saf. 2020 Jan;29(1):18-29. doi: 10.1002/pds.4918.

PMID:
31950565
4.

The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review.

BrintzenhofeSzoc K, Krok-Schoen JL, Canin B, Parker I, MacKenzie AR, Koll T, Vankina R, Hsu CD, Jang B, Pan K, Lund JL, Starbuck E, Shahrokni A.

J Geriatr Oncol. 2020 Apr;11(3):369-379. doi: 10.1016/j.jgo.2019.12.007. Epub 2020 Jan 10. Review.

PMID:
31932259
5.

Association between Concomitant Use of Hydrochlorothiazide and Adverse Chemotherapy-Related Events among Older Women with Breast Cancer Treated with Cyclophosphamide.

Hsu CD, Hinton SP, Reeder-Hayes KE, Sanoff HK, Lund JL.

Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):520-523. doi: 10.1158/1055-9965.EPI-19-1079. Epub 2019 Dec 23.

PMID:
31871107
6.

Oncology pharmacist-led medication reconciliation among cancer patients initiating chemotherapy.

Chun DS, Faso A, Muss HB, Sanoff HK, Valgus J, Lund JL.

J Oncol Pharm Pract. 2019 Dec 18:1078155219892066. doi: 10.1177/1078155219892066. [Epub ahead of print] No abstract available.

PMID:
31852349
7.

Methodological considerations when analysing and interpreting real-world data.

Stürmer T, Wang T, Golightly YM, Keil A, Lund JL, Jonsson Funk M.

Rheumatology (Oxford). 2020 Jan 1;59(1):14-25. doi: 10.1093/rheumatology/kez320.

PMID:
31834408
8.

Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis.

Kirkegård J, Gaber C, Lund JL, Hinton SP, Ladekarl M, Heide-Jørgensen U, Cronin-Fenton D, Mortensen FV.

Cancer Epidemiol. 2020 Feb;64:101647. doi: 10.1016/j.canep.2019.101647. Epub 2019 Dec 5.

PMID:
31811984
9.

Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting.

Pratt NL, Mack CD, Meyer AM, Davis KJ, Hammill BG, Hampp C, Setoguchi S, Raman SR, Chun DS, Stürmer T, Lund JL.

Pharmacoepidemiol Drug Saf. 2020 Jan;29(1):9-17. doi: 10.1002/pds.4924. Epub 2019 Nov 17.

PMID:
31736248
10.

Incidence and risk factors of non-device-associated pneumonia in an acute-care hospital.

Strassle PD, Sickbert-Bennett EE, Klompas M, Lund JL, Stewart PW, Marx AH, DiBiase LM, Weber DJ.

Infect Control Hosp Epidemiol. 2020 Jan;41(1):73-79. doi: 10.1017/ice.2019.300. Epub 2019 Oct 29.

PMID:
31658914
11.

Polypharmacy and Incident Frailty in a Longitudinal Community-Based Cohort Study.

Shmuel S, Lund JL, Alvarez C, Hsu CD, Palta P, Kucharska-Newton A, Jordan JM, Nelson AE, Golightly YM.

J Am Geriatr Soc. 2019 Dec;67(12):2482-2489. doi: 10.1111/jgs.16212. Epub 2019 Oct 24.

PMID:
31648378
12.

Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice.

Mitchell AP, Kinlaw AC, Peacock-Hinton S, Dusetzina SB, Sanoff HK, Lund JL.

Oncologist. 2020 Jan;25(1):46-54. doi: 10.1634/theoncologist.2019-0338. Epub 2019 Oct 14.

13.

Incidence and risk factors of non-device-associated urinary tract infections in an acute-care hospital.

Strassle PD, Sickbert-Bennett EE, Klompas M, Lund JL, Stewart PW, Marx AH, DiBiase LM, Weber DJ.

Infect Control Hosp Epidemiol. 2019 Nov;40(11):1242-1247. doi: 10.1017/ice.2019.241. Epub 2019 Sep 2.

PMID:
31475662
14.

Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries.

Htoo PT, Stürmer T, Jonsson-Funk M, Pate V, Simpson RJ Jr, Lund JL.

Epidemiology. 2019 Nov;30(6):867-875. doi: 10.1097/EDE.0000000000001065.

PMID:
31348009
15.

Geriatric oncology health services research: Cancer and Aging Research Group infrastructure core.

Wong ML, Lichtman SM, Morrow GR, Simmons J, Hargraves T, Gross CP, Lund JL, Lowenstein LM, Walter LC, McDermott CL, Mohile SG, Cohen HJ.

J Geriatr Oncol. 2020 Mar;11(2):350-354. doi: 10.1016/j.jgo.2019.07.012. Epub 2019 Jul 17. No abstract available.

PMID:
31326392
16.

Disparities in Mortality from Noncancer Causes among Adolescents and Young Adults with Cancer.

Anderson C, Lund JL, Weaver MA, Wood WA, Olshan AF, Nichols HB.

Cancer Epidemiol Biomarkers Prev. 2019 Sep;28(9):1417-1426. doi: 10.1158/1055-9965.EPI-18-1384. Epub 2019 Jun 17.

17.

Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.

Garry EM, Buse JB, Gokhale M, Lund JL, Nielsen ME, Pate V, Stürmer T.

Diabetes Obes Metab. 2019 Sep;21(9):2096-2106. doi: 10.1111/dom.13774. Epub 2019 Jun 17.

PMID:
31087620
18.

Health Care Utilization and Comorbidity History of North Carolina Medicaid Beneficiaries in a Controlled Substance "Lock-in" Program.

Naumann RB, Marshall SW, Lund JL, Skinner AC, Ringwalt C, Gottfredson NC.

N C Med J. 2019 May-Jun;80(3):135-142. doi: 10.18043/ncm.80.3.135.

19.

Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research.

Yang JY, Webster-Clark M, Lund JL, Sandler RS, Dellon ES, Stürmer T.

Gastrointest Endosc. 2019 Sep;90(3):360-369. doi: 10.1016/j.gie.2019.04.236. Epub 2019 Apr 30. Review.

PMID:
31051156
20.

Beliefs About Advanced Cancer Curability in Older Patients, Their Caregivers, and Oncologists.

Loh KP, Mohile SG, Lund JL, Epstein R, Lei L, Culakova E, McHugh C, Wells M, Gilmore N, Mohamed MR, Kamen C, Aarne V, Conlin A, Bearden J 3rd, Onitilo A, Wittink M, Dale W, Hurria A, Duberstein P.

Oncologist. 2019 Jun;24(6):e292-e302. doi: 10.1634/theoncologist.2018-0890. Epub 2019 Apr 23.

21.

Author's Reply to: "Design flaws in statins and pancreatic cancer research" (IJC-19-0941).

Kirkegård J, Lund JL, Mortensen FV, Cronin-Fenton D.

Int J Cancer. 2019 Sep 1;145(5):1450-1451. doi: 10.1002/ijc.32349. Epub 2019 May 12. No abstract available.

PMID:
30994188
22.

Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies.

Engeda JC, Stackhouse A, White M, Rosamond WD, Lhachimi SK, Lund JL, Keyserling TC, Avery CL.

Diabetes Res Clin Pract. 2019 May;151:96-105. doi: 10.1016/j.diabres.2019.04.005. Epub 2019 Apr 4.

PMID:
30954511
23.

Restriction of Pharmacoepidemiologic Cohorts to Initiators of Medications in Unrelated Preventive Drug Classes to Reduce Confounding by Frailty in Older Adults.

Zhang HT, McGrath LJ, Ellis AR, Wyss R, Lund JL, Stürmer T.

Am J Epidemiol. 2019 Jul 1;188(7):1371-1382. doi: 10.1093/aje/kwz083.

PMID:
30927359
24.

Noncancer mortality among adolescents and young adults with cancer.

Anderson C, Lund JL, Weaver MA, Wood WA, Olshan AF, Nichols HB.

Cancer. 2019 Jun 15;125(12):2107-2114. doi: 10.1002/cncr.32063. Epub 2019 Mar 20.

25.

Development and validation of a 5-year mortality prediction model using regularized regression and Medicare data.

Lund JL, Kuo TM, Brookhart MA, Meyer AM, Dalton AF, Kistler CE, Wheeler SB, Lewis CL.

Pharmacoepidemiol Drug Saf. 2019 May;28(5):584-592. doi: 10.1002/pds.4769. Epub 2019 Mar 19.

PMID:
30891850
26.

Geriatric Assessment Predicts Hospitalization Frequency and Long-Term Care Use in Older Adult Cancer Survivors.

Williams GR, Dunham L, Chang Y, Deal AM, Pergolotti M, Lund JL, Guerard E, Kenzik K, Muss HB, Sanoff HK.

J Oncol Pract. 2019 May;15(5):e399-e409. doi: 10.1200/JOP.18.00368. Epub 2019 Mar 14.

PMID:
30870086
27.

Statins and pancreatic cancer risk in patients with chronic pancreatitis: A Danish nationwide population-based cohort study.

Kirkegård J, Lund JL, Mortensen FV, Cronin-Fenton D.

Int J Cancer. 2020 Feb 1;146(3):610-616. doi: 10.1002/ijc.32264. Epub 2019 Mar 28.

PMID:
30861115
28.

Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients.

Mayer SE, Tan HJ, Peacock Hinton S, Sanoff HK, Stürmer T, Hester LL, Faurot KR, Jonsson Funk M, Lund JL.

Med Care. 2019 Apr;57(4):286-294. doi: 10.1097/MLR.0000000000001073.

29.

Burden and Cost of Outpatient Hemorrhoids in the United States Employer-Insured Population, 2014.

Yang JY, Peery AF, Lund JL, Pate V, Sandler RS.

Am J Gastroenterol. 2019 May;114(5):798-803. doi: 10.14309/ajg.0000000000000143.

PMID:
30741736
30.

Preadmission use of antidepressants and risk of complications and death after colorectal cancer surgery: a nationwide population-based cohort study.

Lycke KD, Christiansen CF, Lund JL, Iversen LH, Nørgaard M.

Colorectal Dis. 2019 Jun;21(6):651-662. doi: 10.1111/codi.14579. Epub 2019 Mar 6.

PMID:
30740875
31.

Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.

Mitchell AP, Winn AN, Lund JL, Dusetzina SB.

Oncologist. 2019 May;24(5):632-639. doi: 10.1634/theoncologist.2018-0423. Epub 2019 Feb 6.

32.

Pharmacoepidemiology and Drug Safety's special issue on validation studies.

Chun DS, Lund JL, Stürmer T.

Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):123-125. doi: 10.1002/pds.4694. Epub 2019 Feb 3. No abstract available.

PMID:
30714240
33.

The importance and implications of comparator selection in pharmacoepidemiologic research.

D'Arcy M, Stürmer T, Lund JL.

Curr Epidemiol Rep. 2018 Sep;5(3):272-283. doi: 10.1007/s40471-018-0155-y. Epub 2018 Jul 6.

34.

Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

Hester LL, Park SI, Wood WA, Stürmer T, Brookhart MA, Lund JL.

Cancer. 2019 Apr 1;125(7):1101-1112. doi: 10.1002/cncr.31821. Epub 2018 Dec 11.

35.

Trends in Incidence of ACL Reconstruction and Concomitant Procedures Among Commercially Insured Individuals in the United States, 2002-2014.

Herzog MM, Marshall SW, Lund JL, Pate V, Mack CD, Spang JT.

Sports Health. 2018 Nov/Dec;10(6):523-531. doi: 10.1177/1941738118803616.

36.

Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018.

Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, Jensen ET, Shaheen NJ, Barritt AS, Lieber SR, Kochar B, Barnes EL, Fan YC, Pate V, Galanko J, Baron TH, Sandler RS.

Gastroenterology. 2019 Jan;156(1):254-272.e11. doi: 10.1053/j.gastro.2018.08.063. Epub 2018 Oct 10. Review. Erratum in: Gastroenterology. 2019 May;156(6):1936.

37.

Diagnostic Assessment of Assumptions for External Validity: An Example Using Data in Metastatic Colorectal Cancer.

Webster-Clark MA, Sanoff HK, Stürmer T, Peacock Hinton S, Lund JL.

Epidemiology. 2019 Jan;30(1):103-111. doi: 10.1097/EDE.0000000000000926.

38.

Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.

Van Rompay MI, Curtis Nickel J, Ranganathan G, Kantoff PW, Solomon KR, Lund JL, McKinlay JB.

BJU Int. 2019 Mar;123(3):511-518. doi: 10.1111/bju.14534. Epub 2018 Oct 24.

39.

Inflammatory markers and overall survival in older adults with cancer.

Nishijima TF, Deal AM, Lund JL, Nyrop KA, Muss HB, Sanoff HK.

J Geriatr Oncol. 2019 Mar;10(2):279-284. doi: 10.1016/j.jgo.2018.08.004. Epub 2018 Aug 18.

PMID:
30131235
40.

Body mass index, calcium supplementation and risk of colorectal adenomas.

Barry EL, Lund JL, Westreich D, Mott LA, Ahnen DJ, Beck GJ, Bostick RM, Bresalier RS, Burke CA, Church TR, Rees JR, Robertson DJ, Baron JA.

Int J Cancer. 2019 Feb 1;144(3):448-458. doi: 10.1002/ijc.31803. Epub 2018 Oct 30.

41.

Opioid tolerance and clinically recognized opioid poisoning among patients prescribed extended-release long-acting opioids.

Young JC, Lund JL, Dasgupta N, Jonsson Funk M.

Pharmacoepidemiol Drug Saf. 2019 Jan;28(1):39-47. doi: 10.1002/pds.4572. Epub 2018 Jun 11.

PMID:
29888409
42.

Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG).

Yuan H, Ali MS, Brouwer ES, Girman CJ, Guo JJ, Lund JL, Patorno E, Slaughter JL, Wen X, Bennett D; ISPE Comparative Effectiveness Research Special Interest Group.

Clin Pharmacol Ther. 2018 Aug;104(2):239-241. doi: 10.1002/cpt.1086. Epub 2018 May 7.

PMID:
29733448
43.

Trajectories of dispensed prescription opioids among beneficiaries enrolled in a Medicaid controlled substance "lock-in" program.

Naumann RB, Marshall SW, Gottfredson NC, Lund JL, Ringwalt CL, Skinner AC.

Pharmacoepidemiol Drug Saf. 2019 Jan;28(1):16-24. doi: 10.1002/pds.4445. Epub 2018 Apr 26.

PMID:
29700904
44.

Frequency of Care and Mortality Following an Incident Diagnosis of Peripheral Artery Disease in the Inpatient or Outpatient Setting: The ARIC (Atherosclerosis Risk in Communities) Study.

Kalbaugh CA, Loehr L, Wruck L, Lund JL, Matsushita K, Bengtson LGS, Heiss G, Kucharska-Newton A.

J Am Heart Assoc. 2018 Apr 13;7(8). pii: e007332. doi: 10.1161/JAHA.117.007332.

45.

Controlling for Frailty in Pharmacoepidemiologic Studies of Older Adults: Validation of an Existing Medicare Claims-based Algorithm.

Cuthbertson CC, Kucharska-Newton A, Faurot KR, Stürmer T, Jonsson Funk M, Palta P, Windham BG, Thai S, Lund JL.

Epidemiology. 2018 Jul;29(4):556-561. doi: 10.1097/EDE.0000000000000833.

46.

Lower Cancer Incidence-Warfarin Effect or Immortal Time Bias?

Li X, Lund JL, Toh S.

JAMA Intern Med. 2018 Apr 1;178(4):584-585. doi: 10.1001/jamainternmed.2018.0367. No abstract available.

PMID:
29610881
47.

Frailty and Comorbidities Among Survivors of Adolescent and Young Adult Cancer: A Cross-Sectional Examination of a Hospital-Based Survivorship Cohort.

Smitherman AB, Anderson C, Lund JL, Bensen JT, Rosenstein DL, Nichols HB.

J Adolesc Young Adult Oncol. 2018 Jun;7(3):374-383. doi: 10.1089/jayao.2017.0103. Epub 2018 Mar 23.

48.

The incremental value of a geriatric assessment-derived three-item scale on estimating overall survival in older adults with cancer.

Nishijima TF, Deal AM, Lund JL, Nyrop KA, Muss HB, Sanoff HK.

J Geriatr Oncol. 2018 Jul;9(4):329-336. doi: 10.1016/j.jgo.2018.01.007. Epub 2018 Feb 13.

PMID:
29426572
49.

Patient-Reported Comorbidity and Survival in Older Adults with Cancer.

Williams GR, Deal AM, Lund JL, Chang Y, Muss HB, Pergolotti M, Guerard EJ, Shachar SS, Wang Y, Kenzik K, Sanoff HK.

Oncologist. 2018 Apr;23(4):433-439. doi: 10.1634/theoncologist.2017-0404. Epub 2017 Dec 14.

50.

Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding.

Lund JL, Horváth-Puhó E, Komjáthiné Szépligeti S, Sørensen HT, Pedersen L, Ehrenstein V, Stürmer T.

Clin Epidemiol. 2017 Nov 23;9:611-626. doi: 10.2147/CLEP.S147175. eCollection 2017.

Supplemental Content

Support Center